Indefinite Delivery Contract 75D30125D20474
Award Date
6/1/25
Last Date to Order
5/31/26
Federal Agency
CDC Pittsburgh
Awardee
Pfizer Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a leading global pharmaceutical corporation. The $425.5 million IDC, with a period of performance running from June 2023 to June 2024, is for the procurement of adult COVID-19 vaccines. As a major supplier of pharmaceutical products and vaccines to the U.S. federal government, Pfizer holds several significant Indefinite Delivery Vehicles (IDVs),...
This Indefinite Delivery Contract (IDC) with a ceiling value of $347,200,000.00 was awarded to Pfizer Inc. on June 1, 2024 by the Centers for Disease Control and Prevention (CDC) to provide COVID-19 adult vaccines. The contract has a period of performance through September 30, 2025 and was awarded without any set-aside designation, reflecting Pfizer's status as a large pharmaceutical corporation. Under this IDC, Pfizer will supply a variety of adult vaccines to support the CDC's public health...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a global pharmaceutical manufacturer, to provide COVID-19 pediatric vaccines. The contract has a ceiling value of $1,096,801,491.00 and a period of performance running through September 30, 2025. As the prime contractor, Pfizer will deliver a range of critical pharmaceutical products to support various federal healthcare programs, including the Vaccines for Children (VFC)...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, for the procurement of pediatric COVID-19 vaccines. The contract has a total ceiling value of $1,009,243,769 and a period of performance from June 1, 2025, through May 31, 2026. The primary objective of this IDC is to provide the CDC with a reliable source for pediatric COVID-19 vaccines to support the Vaccines for Children (VFC)...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. for the purchase of various adult vaccines. The $118.2 million contract, running from July 1, 2024 to June 30, 2025, covers a diverse array of vaccines including Hepatitis, HPV, Measles/Mumps/Rubella, Meningococcal, Mpox, Pneumococcal, and Varicella. The contract does not utilize any set-asides and allows for...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. to purchase a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.5 billion contract has a period of performance from April 1, 2023 to March 31, 2024. The contract will procure a minimum of 100 doses up to maximum quantities ranging from 100,000 to 13 million doses for 21...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc. for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children aged 0 through 18 years. The contract has a $1,075,250,000.00 ceiling value and a performance period ending on June 6, 2024. The vaccines procured under this multiple-award IDC will support pediatric immunization programs through the Vaccines...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $66,935,445.85 and a period of performance from October 8, 2020 to October 7, 2025, with four one-year option periods. The purpose of this IDC is to provide the U.S. federal government with a source for Epoetin vials, a critical pharmaceutical product. As one of the world's largest pharmaceutical companies, Pfizer...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. for the purchase of 27 different pediatric vaccines to support the CDC's Immunization Awardees program and Vaccines for Children program. The contract has a period of performance from April 1, 2024 to March 31, 2025 and a ceiling value of $1,914,795,500.00. The solicitation sought offers for the supply of...